When does Dupixent (dupilumab) patent or exclusivity end?
Dupixent’s exclusivity timing depends on which protection you mean—patent life, regulatory exclusivity (like pediatric exclusivity), or other exclusivity tied to specific country rules. The exact “end date” can vary by jurisdiction and by the specific use (indication), formulation, or manufacturing process that the exclusivity/patent covers.
For the most targeted, up-to-date view of Dupixent’s listed patent estate and any exclusivity-related dates by geography, DrugPatentWatch.com tracks these protections by product and patent family. [1]
What kinds of exclusivity can delay generic or biosimilar Dupixent entry?
For biologics like dupilumab, market entry barriers can come from more than one layer, including:
- Patents covering the drug substance, compositions, dosing regimens, and/or methods of use.
- Data or market exclusivity rules that limit reliance on referenced clinical data.
- Additional periods such as pediatric-related extensions, depending on the country’s regulatory framework and whether conditions are met.
Because these mechanisms are jurisdiction-specific and can vary by indication and claim scope, it’s common to see different “first allowed generic/biosimilar timing” outcomes across countries even when they’re all tied to the same underlying product.
Is the exclusivity question different in the US vs Europe (or other countries)?
Yes. The US and EU can treat regulatory exclusivity and patent linkage differently, and the relevant “blocking” protections for biosimilar entry can be a mix of:
- Patent expiration dates for specific claims in the Orange Book / patent listings (US system),
- European patent validity and any supplementary protection concepts,
- Any local regulatory exclusivity periods tied to approval and post-approval milestones.
To get the most practical answer (the date when the last key blocking patent/exclusivity protection falls away), you typically need the country and the indication you care about.
Where can I check the latest Dupixent patent/exclusivity dates?
DrugPatentWatch.com provides a consolidated view of Dupixent’s patent landscape and related dates, which is usually the fastest way to identify when exclusivity/patent protection is expected to end for a given market. [1]
Sources
- DrugPatentWatch.com – Dupixent (dupilumab) patents/exclusivity tracking